摘要
重组蛋白和单克隆抗体等高剂量生物制品的生产,给下游分离纯化技术带来了巨大挑战,膜分离技术已成为确保现代生物制品纯度、安全和效用的基本技术。在基因重组人血白蛋白的纯化过程中,膜分离技术同样发挥了不可替代的作用。实验筛选出适合工业化生产的膜组件UFP-750,并优化了操作工艺。实验结果表明,膜组件UFP-750较其他膜组件,膜过滤滤液质量稳定,产品收率较高,选择的最佳控制参数为跨膜压差为50 k Pa、操作温度为15℃。
The production of high-dose biological products,such as recombinant protein and monoclonal antibody,has brought great challenges to downstream purification technology.Membrane separation technology has become the basic technology to ensure the purity,safety and utility of the modern biological products.The membrane separation technology also plays an irreplaceable role in the purification process of rHSA(recombinant Human Serum Albumin).The UFP-750,which is suitable for industrial production was selected and optimized.The experiment results show that the filtrate quality using the membrane component UFP-750 is more stable than other membrane components,and the product yield is high.The membrane pressure 50 kPa and the temperature 15℃are the the best control parameters.
作者
王宗太
马宁宁
Wang Zongtai;Ma Ningning(Shenyang Pharmaceutical University,Shenyang 110016 China;NCPC Biotechnology Branch,Shijiazhuang 056215 China)
出处
《煤炭与化工》
CAS
2018年第5期128-130,154,共4页
Coal and Chemical Industry
基金
"重大新药创制"科技重大专项(2009ZX09313-018)
国家重点新产品项目(2012GRA20001)
